Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 97 of the 97 references it cites were found in a registry or an index.

Therapeutic Targets of KRAS in Colorectal Cancer

Open access

Abstract

Patients with metastatic colorectal cancer have a 5-year overall survival of less than 10%. Approximately 45% of patients with metastatic colorectal cancer harbor KRAS mutations. These mutations not only carry a predictive role for the absence of response to anti-EGFR therapy, but also have a negative prognostic impact on the overall survival. There is a growing unmet need for a personalized therapy approach for patients with KRAS-mutant colorectal cancer. In this article, we focus on the therapeutic strategies targeting KRAS- mutant CRC, while reviewing and elaborating on the discovery and physiology of KRAS.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/cancers13246233

Cites

97 of 97 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Signaling pathways downstream of RAS and potential targets. RAS directly activates the mitogen activated protein kinase (MAPK) cascade, through phosphorylation of Raf (Rapidly accelerated fibro sarcoma) which in turn phosphorylates MEK (Mitogen activated protein kinase kinase), which then phosphorylates MAPK. On the other hand, it also interacts with the PI3K (Phosphatidylinositol-4,5-Bisphosphate 3-Kinase)/AKT (serine/threonine protein kinase) pathway, either by PI3K interaction or through RAC1 which in turn activates p21-activated kinase (PAK), an AKT interacting protein. RAS also activates the RAL (RAS like proto-oncogene) which is involved in various steps of membrane trafficking. The PLCs (Phospholipase C) along with RINI/ABL plays important role in cytoskeletal remodeling. The activation of NORE1/RASSF1 is involved in cell cycle arrest and apoptosis.
Figure 1 Signaling pathways downstream of RAS and potential targets. RAS directly activates the mitogen activated protein kinase (MAPK) cascade, through phosphorylation of Raf (Rapidly accelerated fibro sarcoma) which in turn phosphorylates MEK (Mitogen activated protein kinase kinase), which then phosphorylates MAPK. On the other hand, it also interacts with the PI3K (Phosphatidylinositol-4,5-Bisphosphate 3-Kinase)/AKT (serine/threonine protein kinase) pathway, either by PI3K interaction or through RAC1 which in turn activates p21-activated kinase (PAK), an AKT interacting protein. RAS also activates the RAL (RAS like proto-oncogene) which is involved in various steps of membrane trafficking. The PLCs (Phospholipase C) along with RINI/ABL plays important role in cytoskeletal remodeling. The activation of NORE1/RASSF1 is involved in cell cycle arrest and apoptosis.CC BY · PubMed Central
Figure 2 This figure shows that the G-quadruplex (G4) structures and the inhibition of the G4 structure on KRAS promoter region can cause downregulation of gene expression in CRC cell lines.
Figure 2 This figure shows that the G-quadruplex (G4) structures and the inhibition of the G4 structure on KRAS promoter region can cause downregulation of gene expression in CRC cell lines.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 96 references

Research works printed but not linked: 1

  1. Therapeutics, M. (2021, October 28). Mirati Therapeutics Reports Investigational Adagrasib (MRTX849) Preliminary Data Demonstrating Tolerability and Durable Anti-Tumor Activity as Well as Initial MRTX1133 Preclinical Data. Available online: https://ir.mirati.com/press-releases/press-release-details/2020/Mirati-Therapeutics-Reports-Investigational-Adagrasib-MRTX849-Preliminary-Data-Demonstrating-Tolerability-and-Durable-Anti-Tumor-Activity-as-well-as-Initial-MRTX1133-Preclinical-Data/default.aspx.

Cited by

See all 29

Metadata

Authors
Rahman, S., Garrel, S., Gerber, M., Maitra, R., & Goel, S.
Affiliations
  • Albert Einstein College of Medicine (US)
  • Lander University (US)
  • Yeshiva University (US)
Corresponding author
Goel, Sanjay
Venue
Cancers
Publisher
MDPI AG
Published
2021-12-11
Volume
13
Issue
24
Pages
6233
ISSN
2072-6694 (ISSN-L)
OpenAlex
W4200211768
Cited by
28
References
96
Citations by year
2026: 3 · 2025: 5 · 2024: 8 · 2023: 11 · 2022: 1
FWCI
0.64
Type
journal article
Language
en
Open access
Locations
  • Cancers (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • National Institutes of Health (R21 AG058027 02 ( NIA))
  • Yeshiva University (252869-252929, 2A4108)
Topics
  • Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Keywords
KRAS mutation, metastatic colorectal cancer, KRAS-targeted therapy, anti-EGFR therapy resistance, prognostic factors, personalized treatment, therapeutic target

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Therapeutic Targets of KRAS in Colorectal Cancer. https://app.cochat.ai/papers/10.3390/cancers13246233
The paper
Rahman, S., Garrel, S., Gerber, M., Maitra, R., & Goel, S. (2021). Therapeutic Targets of KRAS in Colorectal Cancer. Cancers. https://doi.org/10.3390/cancers13246233

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.